FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978492747> ?p ?o ?g. }

• W2978492747 endingPage "v774" @default.
• W2978492747 startingPage "v774" @default.
• W2978492747 abstract "Abstract Background Irinotecan is widely used, but also known for its severe toxicities neutropenia and diarrhea. Based on preclinical data, combined caloric and protein restriction (CCPR) might improve treatment tolerability without impairing antitumor effect. Therefore, we studied the influence of CCPR on irinotecan pharmacokinetics and toxicity. Methods In this cross-over trial, patients with liver metastases of solid tumors were included and randomized to treatment with irinotecan preceded by 5 days of CCPR (∼30% caloric and ∼70% protein restriction) during the 1st cycle and a 2nd cycle preceded by a normal diet (ND) or vice versa. During both cycles, 24-hours blood sampling was performed and 24-26 hours after infusion biopsies of both healthy liver (HL) and liver metastasis (LM) were taken. Primary endpoint was the relative difference in geometric means for the active metabolite SN-38 concentration in HL, as analyzed by a linear mixed model. Secondary endpoints included irinotecan and SN-38 concentrations in LM, plasma area under the curve (AUC0-24h), and toxicity. Results Interpatient variability (n = 19) in tissue irinotecan and SN-38 concentrations was high, showing no significant differences in irinotecan (+16.8%, 95% CI: -9.7-51.1%, P = 0.227) and SN-38 (+9.8%, 95% CI: -16.4-44.2%, P = 0.48) concentrations between CCPR and ND in HL, as well as in LM (irinotecan: -38.8%, 90% CI: -59.3:-7.9%, P = 0.05 and SN-38: -13.8%, 90% CI:-40.7-25.4%, P = 0.50). CCPR increased irinotecan plasma AUC0-24h with 7.1% (95% CI: 0.3-14.5%, P = 0.04) compared to ND, while the SN-38 plasma AUC0-24h increased with 50.3% (95% CI: 34.6-67.9%, P  Conclusions CCPR resulted in a dramatically increased plasma SN-38 exposure, while toxicity did not change. CCPR did not result in altered irinotecan and SN-38 exposure in HL and LM. CCPR might therefore potentially improve the therapeutic window in patients treated with irinotecan. Clinical trial identification Netherlands Trial Register NL5624 (NTR5731) release date: 2016-03-04. Legal entity responsible for the study A.H.J. Mathijssen. Funding Has not received any funding. Disclosure S.L. Koolen: Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Pfizer; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Cristal Therapeutics; Travel / Accommodation / Expenses: Ipsen. R.H.J. Mathijssen: Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Cristal Therapeutics; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pamgene; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi; Honoraria (institution): Servier; Honoraria (institution): Novartis; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Astellas. All other authors have declared no conflicts of interest." @default.
• W2978492747 created "2019-10-10" @default.
• W2978492747 creator A5008497236 @default.
• W2978492747 creator A5016274586 @default.
• W2978492747 creator A5016592997 @default.
• W2978492747 creator A5019741685 @default.
• W2978492747 creator A5034586704 @default.
• W2978492747 creator A5035765579 @default.
• W2978492747 creator A5038016851 @default.
• W2978492747 creator A5038198323 @default.
• W2978492747 creator A5040739222 @default.
• W2978492747 creator A5042896767 @default.
• W2978492747 creator A5044567914 @default.
• W2978492747 creator A5045236213 @default.
• W2978492747 creator A5047240860 @default.
• W2978492747 creator A5055525702 @default.
• W2978492747 creator A5072400728 @default.
• W2978492747 creator A5086856138 @default.
• W2978492747 creator A5089334712 @default.
• W2978492747 date "2019-10-01" @default.
• W2978492747 modified "2023-10-18" @default.
• W2978492747 title "Effects of dietary restriction in cancer patients receiving irinotecan" @default.
• W2978492747 doi "https://doi.org/10.1093/annonc/mdz268.040" @default.
• W2978492747 hasPublicationYear "2019" @default.
• W2978492747 type Work @default.
• W2978492747 sameAs 2978492747 @default.
• W2978492747 citedByCount "0" @default.
• W2978492747 crossrefType "journal-article" @default.
• W2978492747 hasAuthorship W2978492747A5008497236 @default.
• W2978492747 hasAuthorship W2978492747A5016274586 @default.
• W2978492747 hasAuthorship W2978492747A5016592997 @default.
• W2978492747 hasAuthorship W2978492747A5019741685 @default.
• W2978492747 hasAuthorship W2978492747A5034586704 @default.
• W2978492747 hasAuthorship W2978492747A5035765579 @default.
• W2978492747 hasAuthorship W2978492747A5038016851 @default.
• W2978492747 hasAuthorship W2978492747A5038198323 @default.
• W2978492747 hasAuthorship W2978492747A5040739222 @default.
• W2978492747 hasAuthorship W2978492747A5042896767 @default.
• W2978492747 hasAuthorship W2978492747A5044567914 @default.
• W2978492747 hasAuthorship W2978492747A5045236213 @default.
• W2978492747 hasAuthorship W2978492747A5047240860 @default.
• W2978492747 hasAuthorship W2978492747A5055525702 @default.
• W2978492747 hasAuthorship W2978492747A5072400728 @default.
• W2978492747 hasAuthorship W2978492747A5086856138 @default.
• W2978492747 hasAuthorship W2978492747A5089334712 @default.
• W2978492747 hasBestOaLocation W29784927471 @default.
• W2978492747 hasConcept C121608353 @default.
• W2978492747 hasConcept C126322002 @default.
• W2978492747 hasConcept C143998085 @default.
• W2978492747 hasConcept C2780259306 @default.
• W2978492747 hasConcept C526805850 @default.
• W2978492747 hasConcept C71924100 @default.
• W2978492747 hasConceptScore W2978492747C121608353 @default.
• W2978492747 hasConceptScore W2978492747C126322002 @default.
• W2978492747 hasConceptScore W2978492747C143998085 @default.
• W2978492747 hasConceptScore W2978492747C2780259306 @default.
• W2978492747 hasConceptScore W2978492747C526805850 @default.
• W2978492747 hasConceptScore W2978492747C71924100 @default.
• W2978492747 hasLocation W29784927471 @default.
• W2978492747 hasOpenAccess W2978492747 @default.
• W2978492747 hasPrimaryLocation W29784927471 @default.
• W2978492747 hasRelatedWork W1992982990 @default.
• W2978492747 hasRelatedWork W2020124855 @default.
• W2978492747 hasRelatedWork W2061955988 @default.
• W2978492747 hasRelatedWork W2084101102 @default.
• W2978492747 hasRelatedWork W2093853386 @default.
• W2978492747 hasRelatedWork W2107467998 @default.
• W2978492747 hasRelatedWork W2407153546 @default.
• W2978492747 hasRelatedWork W2898494785 @default.
• W2978492747 hasRelatedWork W2984714837 @default.
• W2978492747 hasRelatedWork W4241435595 @default.
• W2978492747 hasVolume "30" @default.
• W2978492747 isParatext "false" @default.
• W2978492747 isRetracted "false" @default.
• W2978492747 magId "2978492747" @default.
• W2978492747 workType "article" @default.